Stock Movers UnitedHealth Plunges, Eli Lilly Surges, TSMC ADRs Rise on Forecast
Apr 17, 2025
UnitedHealth's shares take a nosedive after missing earnings for the first time in a decade, attributed to rising medical costs. Meanwhile, Eli Lilly's stock soars as new data reveals their experimental weight-loss pill is as effective as the popular Ozempic, edging closer to a needle-free option. TSMC's ADRs thrive on a strong sales forecast for the upcoming quarter, bolstered by expectations of AI revenue growth despite challenging geopolitical climates. The stock market tells a tale of highs and lows!
AI Snips
Chapters
Transcript
Episode notes
UnitedHealth's Rare Earnings Miss
- UnitedHealth's share plunge is the biggest since at least March 2020 due to cutting its annual forecast and a rare earnings miss.
- Rising medical costs, especially in Medicare Advantage and Optum Health, pressured its performance and outlook.
Eli Lilly’s Needle-Free Diabetes Pill
- Eli Lilly's experimental weight-loss pill performed as well as the Ozempic shot, promising a needle-free alternative.
- This pill, called Orforglipron, targets diabetes, obesity, and related conditions, which could revolutionize treatment.
TSMC’s Confident Growth Outlook
- TSMC maintains a bullish growth outlook for 2025 despite U.S.-China trade tensions.
- The company expects AI-related revenue to double, signaling strong confidence in its long-term prospects.